A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
about
Update on the Pathogenic Implications and Clinical Potential of microRNAs in Cardiac DiseaseDelivery of gene silencing agents for breast cancer therapyCUP-1 is a novel protein involved in dietary cholesterol uptake in Caenorhabditis elegansProgress toward in vivo use of siRNAs-IIDeploying RNA and DNA with Functionalized Carbon NanotubesTranscription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.Lipid-like materials for low-dose, in vivo gene silencingClinical status of duplex RNASelf-assembled lipid nanomedicines for siRNA tumor targeting.Lipid and polymeric carrier-mediated nucleic acid delivery.Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid TumorsDelivery of siRNA therapeutics: barriers and carriers.Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugationIn vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weightA novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitisImaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA.Nanogyroids incorporating multivalent lipids: enhanced membrane charge density and pore forming ability for gene silencing.Nanoparticle PEGylation for imaging and therapy.Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability.Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis.The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.Hydrophobization and bioconjugation for enhanced siRNA delivery and targetingDegradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media.The role and source of tumor necrosis factor-α in hemorrhage-induced priming for septic lung injury.Current progress of siRNA/shRNA therapeutics in clinical trials.Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE(-/-) Mice.Oxime ether lipids containing hydroxylated head groups are more superior siRNA delivery agents than their nonhydroxylated counterparts.Short-interference RNAs: becoming medicines.Effect of surface properties on liposomal siRNA delivery.Molecular targeting of liposomal nanoparticles to tumor microenvironment.Gene control of tyrosine kinase TIE2 and vascular manifestations of infections.Gene therapy for the prevention of vein graft diseaseDelivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.Modulating the expression of disease genes with RNA-based therapy.RNA interference and antiviral therapy.Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery.Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA.
P2860
Q26801907-A5D529CD-DABC-4B24-B05D-6B1C0656B58FQ27008706-38F21BB7-9B71-43DA-803B-BAD6F1607D62Q27305927-0CCE75CD-060D-45DD-BD61-37123037BE06Q28255877-5EB2B496-EA00-4E54-9177-E596A267A8B0Q28468241-A397F113-E35F-43F4-9617-E84B40391ED4Q28771711-D6AE9C9E-2FA9-4514-9689-6AEE2C1C77E3Q33583399-61B9FFD5-0446-40E9-8355-D35AC0EBCBD9Q33869361-D0A32DC2-237A-4E70-9414-2A9156D75D52Q33907953-DB5280B7-5606-43EA-9D55-4C501732FA68Q34155795-22CF9F2E-6192-4E5C-8194-01B1F8F708DDQ34160892-6CCA88FA-DEBA-497B-BE59-0E39CBA66FC0Q34165321-D0462AFE-D905-47B1-A9E4-E5531F1B91A0Q34293708-6B74B460-97DE-4D75-96EA-64B7BBFDC36DQ34389283-1E951502-0207-4B89-8622-0403D181F628Q34393539-E529C038-B0A3-4C3A-85A2-AFCA622B9205Q34412219-476D6DDB-EA62-4701-8415-EC2A7885C187Q34640040-DA4DA603-4559-4F08-A7AC-695141894FE3Q35058472-582A0E04-5935-465A-A609-48A15BFC048DQ35553193-6916BE4C-CEF4-4CC9-87F8-E9A4FC82843EQ35595798-DC8F373A-3A7D-4FE0-8452-3D4EA4DC3775Q35597977-911BF657-E256-4F38-8802-6B994A78DCA0Q35640140-2FEC5DFA-4C37-4AC3-AE7D-7E98B9714D3FQ35665154-EAE328DC-B646-47A4-B584-235A47E59566Q35697443-F106AD68-CEBA-4E88-82CC-79ABBE8FC915Q35867148-4B1C10CF-B949-433C-A057-4A45B895B172Q35973583-6D56C85C-06BB-40B4-A7BE-BE94F098EE71Q36071638-FDB7B7E0-EB2A-4429-AB1D-FB42C40A9B8BQ36089057-DA081DB2-6CAE-4E89-BCFD-263A614F41A1Q36257158-C815F14D-57E8-400E-BBB8-6590EAC5C37FQ36347546-C9D9A448-2048-4C1C-BAEE-BD948C6526BCQ36421379-EAEB91EC-37FB-430B-9D14-62361D387ECAQ36500108-44B825F5-8C6B-469F-86F5-9ED8FB194544Q36658971-3056CB0C-91AD-4307-AAEC-A1C7CB1BDBA6Q36698258-4B9B0BBF-00E1-4260-9A91-58608859FD35Q36791673-6C91C85B-DBBE-4834-9C8B-1DBDA780D020Q36848111-BA040320-1A9F-484E-B52D-1100340A95F4Q36866549-36D566A5-0539-4467-9F0A-330879559413Q36944914-3C580FAD-539B-4EC8-8D39-0C0A1D9460E3Q36960492-9F02CA10-0419-4D73-A055-100F445D424EQ36968187-61B56070-76E1-44F8-8E0C-0F5A89B00FAB
P2860
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
@en
type
label
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
@en
prefLabel
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
@en
P2093
P2860
P356
P1433
P1476
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
@en
P2093
Endruschat J
Fechtner M
Kaufmann J
P2860
P2888
P304
P356
10.1038/SJ.GT.3302777
P577
2006-04-20T00:00:00Z
P5875
P6179
1007862948